Skip to main content

Branded

  • Teva appoints new president, CEO

    JERUSALEM — Teva Pharmaceutical Industries has appointed Erez Vigodman as president and CEO, the Israeli drug maker said Thursday.

    Vigodman will replace acting president and CEO Eyal Desheh, who will return to his previous position as group EVP and CFO. Desheh took the interim position after the departure of former president and CEO Jeremy Levin in October 2013.

  • NCPA survey: Drugs often don't make it to patients' hands due to efforts to combat prescription drug abuse

    ALEXANDRIA, Va. —Vulnerable patients, including seniors and cancer patients, suffer from lack of access to needed painkillers as efforts to combat diversion and misuse of controlled substances often result in drugs not getting into the hands of those who need them, according to a new pharmacist survey by the National Community Pharmacists Association. 

  • Forest Labs buys specialty drug maker Aptalis

    NEW YORK — Forest Labs will buy privately owned drug maker Aptalis for $2.9 billion, Forest said Thursday.

    Aptalis specializes in making drugs for gastrointestinal disorders and cystic fibrosis, with sales of $688 million in fiscal year 2013. More than 60% of its sales come from the ulcer treatment Carafate (sucralfate), the inflammatory bowel disease treatment Canasa (melamine) and the cystic fibrosis drug Zenpep (pancrelipase).

  • Takeda starts phase-3 trials of vedolizumab

    OSAKA, Japan — Takeda Pharmaceutical has started a late-stage clinical trial program of its experimental drug for inflammatory bowel disease in Japan, the company said Wednesday.

    Takeda announced the start of two phase-3 trials of MLN0002 (vedolizumab) in patients with severe ulcerative colitis and Crohn's disease. The trials are designed to find out the efficacy, safety and effects on the body of the drug, particularly to see if patients show a response after 10 weeks of treatment and disease remission after 60 weeks.

  • Daiichi Sankyo hopes to get FDA nod for anti-clotting drug

    PARSIPPANY, N.J. — Japanese drug maker Daiichi Sankyo is seeking Food and Drug Administration approval for a once-daily tablet to reduce the risk of stroke in patients with atrial fibrillation and treatment of other conditions.

    Daiichi Sankyo announced the submission of a new drug application for Savaysa (edoxaban). The company also is hoping to get the FDA's approval for the pill as a treatment for deep vein thrombosis and pulmonary embolism, as well as preventing the recurrence of symptomatic venous thromboembolism.

  • ECRM unveils ECRM Data, a turnkey solution for promotional tracking and analysis functions

    SOLON, Ohio — Efficient Collaborative Retail Marketing on Wednesday unveiled the ECRM Data web site, ECRMData.com. ECRM Data is an industry solution that offers turnkey solutions for promotional tracking and analysis functions.

  • FDA approves Bristol-Myers Squibb's, AstraZeneca's Farxiga

    SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug made by Bristol-Myers Squibb and AstraZeneca for treating Type 2 diabetes, the agency said Wednesday.

    The FDA announced the approval of Farxiga (dapagliflozin) tablets, designed for use with exercise and dietary adjustments to control blood sugar. Type 2 diabetes affects about 24 million people in the United States, accounting for more than 90% of diabetes cases.

  • Publix extends Sync Your Refills program chainwide

    LAKELAND, Fla. — Publix on Tuesday announced plans to expand a new Sync Your Refills program to all pharmacies. After a successful test in the Atlanta Division, the program will expand companywide to the remaining Publix Pharmacies by Friday, Jan. 24. 

X
This ad will auto-close in 10 seconds